Noninsulin drugs for type 2 diabetes approved by the US Food and Drug Administration since 2005
| Drug | Year approved |
|---|---|
| DPP-4 inhibitors | |
| Sitagliptin (Januvia) | 2006 |
| Saxagliptin (Onglyza) | 2009 |
| Linagliptin (Tradjenta) | 2011 |
| Alogliptin (Nesina) | 2013 |
| GLP-1 receptor agonists | |
| Short-acting (4–6 hrs) | |
| Exenatide (Byetta) | 2005 |
| Lixisenatide (Lyxumia) | NDA submitted |
| Intermediate-acting (24 hrs) | |
| Liraglutide (Victoza) | 2010 |
| Long-acting (7 days) | |
| Exenatide extended-release (Bydureon) | 2012 |
| Albiglutide (Tanzeum) | 2014 |
| Dulaglutide (Trulicity) | 2014 |
| SGLT-2 inhibitors | |
| Canagliflozin (Invokana) | 2013 |
| Dapagliflozin (Farxiga) | 2014 |
| Empagliflozin (Jardiance) | 2014 |
| Bile acid sequestrant | |
| Colesevelam (Welchol) | 2008 |
| Dopamine-receptor agonist | |
| Bromocriptine quick-release (Cycloset) | 2009 |
DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; NDA = new drug application; SGLT-2 = sodium-glucose cotransporter-2.